Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
Claret Capital Partners will invest €43m in Inventiva (Euronext Paris and Nasdaq: IVA) as part of Inventiva’s €130m committed debt financing, with an additional uncommitted tranche of up to €20m, according to the companies. The funding supports Phase 3 development of lanifibranor for MASH; Inventiva expects NATiV3 top-line readout in Q4 2026.
How this was made
The 30-second read
Why it matters
The disclosed €130m committed debt financing (with an additional uncommitted tranche up to €20m) is positioned as capital-structure optimization to fund 2026–2027 clinical/regulatory milestones, which can reduce dilution risk into a pivotal readout.
Market read
A sizable, committed financing package for a late-stage MASH program is a tangible de-risking event ahead of a near-term (Q4 2026) Phase 3 catalyst.
What to watch
The article doesn’t specify interest rate, covenants, or how the uncommitted €20m tranche may depend on milestones—those details could affect perceived risk reduction.
Background
Inventiva is a clinical-stage biopharma developing lanifibranor for MASH and is running the Phase 3 NATiV3 trial with anticipated top-line readout in Q4 2026.
Ticker impact
Inventiva secured €130m debt financing with Claret providing €43m, extending runway for Phase 3 NATiV3 lanifibranor readout in Q4 2026.
Likely supportive for IVA as it de-risks cash runway into Q4 2026 top-line readout, though biotech sentiment may still hinge on trial outcomes.
The article discloses a specific, sizable committed debt package (€130m total; €43m from Claret) tied to advancing lanifibranor through Phase 3, which typically matters for dilution risk and financing overhang.
Market effects
Highlights continued availability of growth debt for late-stage European biotechs, potentially improving sector financing conditions and reducing dilution pressure.
Supports European biotech capital markets activity (Euronext Paris) with cross-border US listing participation.
Reinforces global investor appetite for MASH assets and pan-PPAR oral therapies approaching pivotal Phase 3 catalysts.
Counterpoint
Debt financing can still imply future repayment/covenant constraints; equity upside may be capped if terms are restrictive or if trial risk dominates.
Key entities
- companyInventiva
Clinical-stage biopharmaceutical company advancing lanifibranor in Phase 3 NATiV3 for MASH.
- investorClaret Capital Partners
Growth debt fund manager providing €43m as part of Inventiva’s €130m debt financing.
- investorBlackRock
Manages funds/accounts participating in the total €130m committed tranches.
